---
$id: https://graph.org.ai/products/commodity/51131718
$type: Product
source: UNSPSC
code: "51131718"
title: "Anagrelide"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Anagrelide

**UNSPSC Code**: 51131718
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C10H7Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K9X45X0051, chemically known as 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3h)-one but generally known as anagrelide, which bears US NIH Compound Identifier 2182. Anagrelide most often comes in base and hydrochloride forms. European Medicines Agency schedules Anagrelide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05499MIG. The term ANAGRELIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, No. 10 1980, List 20). World Health Organization schedules anagrelide in its Anatomical Therapeutic Chemical (ATC) Classification. ANAGRELIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule anagrelide under HS 29335995 and SITC 51576. As of Q4 2014, ANAGRELIDE remains the US FDA Preferred Term for this commodity. Anagrelide bears US NLM identifiers UMLS ID C0051809 and NCI Concept Code C28825. SMILES: C1C2=C(C=CC(=C2CL)CL)NC3=NC(=O)CN31.

